TITLE

Acusphere closes $20 million financing deal with Cephalon

PUB. DATE
November 2008
SOURCE
Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the $20 million financing deal reached by Acusphere with Cephalon in November 2008. Included in the deal is a $15 million senior secured convertible note and a $5 million upfront fee for an exclusive global license to A1-525 injectable formulation of celecoxib. Also described are the features of Imagify, the lead product candidate of Acusphere.
ACCESSION #
35066388

 

Related Articles

  • Cephalon scraps all licensing agreements with Acusphere.  // Medical Device Daily;6/26/2009, Vol. 13 Issue 122, p5 

    The article offers updates on Acusphere's agreements with Cephalon in 2009. Acusphere has received a $1 million payment from Cephalon and has canceled Cephalon's $15 million senior secured convertible note. It has also made amendments to its November 2008 license agreements with Cephalon,...

  • $10M Deal: Acusphere Licenses HDDS, Compound to Cephalon. Hollingsworth, Catherine // BioWorld Today;4/1/2008, Vol. 19 Issue 63, p1 

    The article reports on the $10 million deal signed by Acusphere Inc. to license intellectual property rights to its Hydrophobic Drug Delivery System (HDDS) for use in oncology, as well as rights to AI-850, its formulation of paclitaxel, to Cephalon Inc. Sherri C. Oberg, president and CEO of...

  • OTHER NEWS TO NOTE.  // BioWorld Today;10/28/2008, Vol. 19 Issue 210, p2 

    This section offers news briefs on the biotechnology industries. Acusphere Inc. signed an exclusive license agreement for its preclinical nonsteroidal anti-inflammatory drug (NSAID) AI-525 to Cephalon Inc. NexMed Inc. will receive $3.5 million in milestone payments from partner Novartis AG...

  • Lack of funds drives Chad to suspend operations.  // Diagnostics & Imaging Week;11/6/2008, Vol. 11 Issue 45, p3 

    This article briefly discusses financial news relating to the diagnostic equipment industry. An announcement by Chad Therapeutics Inc. that it will suspend operations because of a shortage of capital is presented. An financial arrangement where Acusphere Inc. will receive funding from Cephalon...

  • Acusphere's Shares Plunge on FDA Safety Concerns. Young, Donna // BioWorld Today;12/9/2008, Vol. 19 Issue 238, p3 

    The article reports on the decline in shares of Watertown, Massachusetts-based Acusphere Inc. after concerns with the company's investigational injectable imaging agent Imagify, a drug used in detecting coronary artery disease, were raised by the U.S. Food and Drug Administration (FDA). The FDA...

  • Cephalon Pays $100M for Option on Ception.  // Bioworld Week;1/19/2009, Vol. 17 Issue 3, p3 

    The article reports on the deal made by the Cephalon Inc. to Ception Inc. in giving Ception's options to buy the company. It says that Cephalon has give $100 million upfront payment for an option to buy the company and its main anti-inflammatory product for additional $250 million. It further...

  • Acusphere's $10M Deal with Cephalon.  // Bioworld Week;4/7/2008, Vol. 16 Issue 14, p3 

    The article reports that Acusphere Inc. in Massachusetts has signed a $10 million deal with Cephalon Inc., an international biopharmaceutical company, to license intellectual property rights to its Hydrophobic Drug Delivery System (HDDS) and rights to Al-850, its formulation of paclitaxel. HDDS...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/21/2008, Vol. 19 Issue 99, p2 

    This section offers news briefs concerning biotechnology industries. Payment terms for some intellectual property agreements have been negotiated by Acusphere Inc. Motorplate 96 assay-ready well plates will be provided to BioFocus DPI by California Stem Cell Inc. A nonexclusive STAR research...

  • ImmuPharma, Cephalon Ink Potential $500M Lupuzor Deal. Moran, Nuala // BioWorld International;11/26/2008, Vol. 13 Issue 48, p1 

    The article reports that ImmuPharma plc signed an agreement giving Cephalon Inc. the option on an exclusive, worldwide license to Lupuzor in the treatment of systemic lupus erythematosus. Under the deal, ImmuPharma took $15 million up front as the first payment, and will potentially receive...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics